CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  Approximately 47,560 new cases of head and neck (H&N) cancer are estimated to occur in the United States during 2008, accounting for three percent of all types of cancer, and more than 11,000 patients will die from the disease. Treatment for patients with H&N cancer is complex and requires a multidisciplinary team of individuals with expertise in the special care needs of these patients. The site and extent of disease and pathologic findings dictate the appropriate surgical approach, radiation field, dose and fractionation and indications for chemotherapy and/or biologic therapy. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists and radiation oncologists must be well informed of these advances. To bridge the gap between research and patient care, Head and Neck Cancer Update features one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists these physicians with the formulation of up-to-date clinical management strategies.

  
  LEARNING OBJECTIVES
  • Recognize the role of HPV in the pathogenesis of oropharyngeal cancer, and describe its impact on patient prognosis and response to treatment.
  • Develop evidence-based multimodality treatment approaches for patients with locally advanced and metastatic H&N cancer.
  • Assess the impact of radiation therapy with concurrent chemotherapy and/or EGFR inhibition on treatment tolerability and long-term outcomes.
  • Appraise the merit of intensity-modulated, image-guided radiation therapy in the treatment of H&N cancer.
  • Recommend supportive measures to ameliorate the common toxicities that accompany the local and systemic treatment of H&N cancer.
  • Acknowledge the psychosocial, physical and emotional toll associated with the diagnosis and treatment of H&N cancer.
  • Delineate the rationale for early-phase clinical trials with novel targeted therapies in H&N cancer, including anti-angiogenic agents and multitargeted kinase inhibitors.
  • Counsel appropriately selected patients about participation in ongoing clinical trials.
  ACCREDITATION STATEMENT
   
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  
  CREDIT DESIGNATION STATEMENT
   
  Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
   
  HOW TO USE THIS CME ACTIVITY
   
  CME credit is no longer available for this issue
   
  This CME activity contains both audio and print components. The participant should review the CME information and listen to the audio MP3s. 
  
  CONTENT VALIDATION AND DISCLOSURES
   
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
   
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Langer — Advisory Committee: Abraxis BioScience, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, ImClone Systems Incorporated, OSI Oncology, Pfizer Inc; Consulting Agreements: Amgen Inc, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, GPC Biotech, ImClone Systems Incorporated, OSI Oncology, Pfizer Inc; Speakers Bureau: Abraxis BioScience, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, ImClone Systems Incorporated, OSI Oncology, Pfizer Inc, Sanofi-Aventis. Dr Haddad — Speakers Bureau: Bristol-Myers Squibb Company, Sanofi-Aventis. Dr Rosenthal — Consulting Agreement: Amgen Inc; Paid Research: ImClone Systems Incorporated; Speakers Bureau: Bristol-Myers Squibb Company, ImClone Systems Incorporated. Dr Vokes — Advisory Committee: Bayer Pharmaceuticals Corporation; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, ImClone Systems Incorporated, OSI Oncology, Sanofi-Aventis.
   
  EDITOR — Dr Love does not receive any direct remuneration from industry. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.
   
  RESEARCH TO PRACTICE STAFF AND EXTERNAL
  
  REVIEWERS — The scientific staff and reviewersfor Research To Practice have no real or apparent conflicts of interest to disclose.

  ---

  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  
  This program is supported by educational grants from AstraZeneca Pharmaceuticals LP and ImClone Systems Incorporated.
  
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: December 2008
  Expiration date: December 2009